These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 20187712)

  • 21. Myasthenia gravis studied by monoclonal antibodies to the acetylcholine receptor.
    Tzartos SJ
    In Vivo; 1988; 2(1):105-10. PubMed ID: 2979808
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Specific adsorbents for myasthenia gravis autoantibodies using mutants of the muscle nicotinic acetylcholine receptor extracellular domains.
    Lazaridis K; Evaggelakou P; Bentenidi E; Sideri A; Grapsa E; Tzartos SJ
    J Neuroimmunol; 2015 Jan; 278():19-25. PubMed ID: 25595248
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Therapeutic strategy in myasthenia gravis].
    Tranchant C
    Rev Neurol (Paris); 2009 Feb; 165(2):149-54. PubMed ID: 19233080
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Specific immunoadsorption of the autoantibodies from myasthenic patients using the extracellular domain of the human muscle acetylcholine receptor alpha-subunit. Development of an antigen-specific therapeutic strategy.
    Psaridi-Linardaki L; Trakas N; Mamalaki A; Tzartos SJ
    J Neuroimmunol; 2005 Feb; 159(1-2):183-91. PubMed ID: 15652418
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Anti-acetylcholinesterase antibodies associate with ocular myasthenia gravis.
    Provenzano C; Marino M; Scuderi F; Evoli A; Bartoccioni E
    J Neuroimmunol; 2010 Jan; 218(1-2):102-6. PubMed ID: 19942297
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical correlates with anti-MuSK antibodies in generalized seronegative myasthenia gravis.
    Evoli A; Tonali PA; Padua L; Monaco ML; Scuderi F; Batocchi AP; Marino M; Bartoccioni E
    Brain; 2003 Oct; 126(Pt 10):2304-11. PubMed ID: 12821509
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Role of the main immunogenic region of acetylcholine receptor in myasthenia gravis. An Fab monoclonal antibody protects against antigenic modulation by human sera.
    Tzartos SJ; Sophianos D; Efthimiadis A
    J Immunol; 1985 Apr; 134(4):2343-9. PubMed ID: 3973387
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pathophysiology of myasthenia gravis.
    Hughes BW; Moro De Casillas ML; Kaminski HJ
    Semin Neurol; 2004 Mar; 24(1):21-30. PubMed ID: 15229789
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Management of myasthenia gravis.
    Schwendimann RN; Burton E; Minagar A
    Am J Ther; 2005; 12(3):262-8. PubMed ID: 15891271
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Myasthenia gravis: emerging new therapy options.
    Sieb JP
    Curr Opin Pharmacol; 2005 Jun; 5(3):303-7. PubMed ID: 15907918
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Current and future therapies for myasthenia gravis.
    Yi Q; Lefvert AK
    Drugs Aging; 1997 Aug; 11(2):132-9. PubMed ID: 9259176
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment of autoimmune myasthenia gravis.
    Richman DP; Agius MA
    Neurology; 2003 Dec; 61(12):1652-61. PubMed ID: 14694025
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Presence and pathogenic relevance of antibodies to clustered acetylcholine receptor in ocular and generalized myasthenia gravis.
    Jacob S; Viegas S; Leite MI; Webster R; Cossins J; Kennett R; Hilton-Jones D; Morgan BP; Vincent A
    Arch Neurol; 2012 Aug; 69(8):994-1001. PubMed ID: 22689047
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Reduced thymic expression of ErbB receptors without auto-antibodies against synaptic ErbB in myasthenia gravis.
    Vrolix K; Niks EH; Le Panse R; van Ostaijen-Ten Dam MM; Muris AH; Jol-van der Zijde CM; van Tol MJ; Losen M; Molenaar PC; van Zoelen EJ; Berrih-Aknin S; De Baets MH; Verschuuren JJ; Martínez-Martínez P
    J Neuroimmunol; 2011 Mar; 232(1-2):158-65. PubMed ID: 21168922
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Myasthenia gravis: new therapeutic approaches based on pathophysiology.
    Lewis RA
    J Neurol Sci; 2013 Oct; 333(1-2):93-8. PubMed ID: 23938353
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Enzyme-linked immunosorbent assay for antibody against the nicotinic acetylcholine receptor in human myasthenia gravis.
    Kawanami S; Tsuji R; Oda K
    Ann Neurol; 1984 Feb; 15(2):195-200. PubMed ID: 6367620
    [TBL] [Abstract][Full Text] [Related]  

  • 37. FK506 prevents induction of rat experimental autoimmune myasthenia gravis.
    Yoshikawa H; Iwasa K; Satoh K; Takamori M
    J Autoimmun; 1997 Feb; 10(1):11-6. PubMed ID: 9080295
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Experimental models of myasthenia gravis: lessons in autoimmunity and progress toward better forms of treatment.
    Pachner AR
    Yale J Biol Med; 1987; 60(2):169-77. PubMed ID: 3495075
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Myasthenia gravis and myasthenic syndromes.
    Engel AG
    Ann Neurol; 1984 Nov; 16(5):519-34. PubMed ID: 6095730
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Autoimmune responses against acetylcholine receptor: T and B cell collaboration and manipulation by synthetic peptides.
    Atassi MZ; Oshima M
    Crit Rev Immunol; 1997; 17(5-6):481-95. PubMed ID: 9419435
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.